PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today that it has received CE Mark for spineEOS, its online 3D planning software for spine surgery based on EOS bi-planar imaging. spineEOS is third “EOSapp” software planning solution introduced by the Company, joining its hipEOS and kneeEOS products.
The spineEOS online 3D planning software allows a surgeon to utilize 3D imaging provided by the EOS system to create an optimized treatment plan to achieve improved sagittal alignment for pediatric patients with Adolescent Idiopathic Scoliosis as well as adults suffering from degenerative or deformative spine conditions. The software, which provides a treatment simulation based on reference values, takes into account the patient vertebrae shape and position in 3D. The expected surgical correction can be visualized and captured in a planning report. Professor Peter Newton at Rady Children’s Hospital in San Diego, California and Professor Brice Ilharreborde at Debré Hospital in Paris, France are currently conducting clinical studies using the new spineEOS planning software.
The Company will feature all three EOSapps at its booth #2909 at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting, March 1-5 in Orlando, Florida. The Company will also highlight at AAOS the EOS system and related products and services, which provide physicians with the ability to visualize a patient’s anatomy in a weight bearing position, calculate clinical parameters and plan surgeries in 3D without needing costly, high dose CT exams, which image a patient in non-weight bearing position. In addition to the activities at its booth at AAOS, the Company is scheduled to present at the Canaccord Genuity Musculoskeletal Conference in Orlando, Florida on March 1, 2016 at 8:30 am ET. The conference provides the opportunity for institutional investors to meet with the Company.
Marie Meynadier, CEO of EOS imaging, said, “We are looking forward to highlighting our product offering at AAOS and share the value in the orthopaedic space of our EOS imaging platform and new EOSapps. These online 3D surgical planning solutions are a big step towards planning patient-specific procedures in 3D that are cost effective, and provide our company the exciting opportunity to offer full image-based services along key orthopedic care pathways.”
For more information, please visit www.eos-imaging.com.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: 2015 Full-year results and 2016 First-quarter sales on April 28, 2016
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2015 revenues of €21.8 million and employs 107 people including an R&D team of 39 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.